RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
integrating patient reported outcomes for tolerability assessment in early phase clinical trials - insights from an expert virtual roundtable
Yap, C., Lee Aiyegbusi, O., Alger, E., Basch, E., Bell, J., Bhatnagar, V., Cella, D., Collis, P., Dueck, A. C., Gilbert, A., Gnanasakthy, A., Greystoke, A., Hansen, A. R., Kamudoni, P., Kholmanskikh, O., King-Kallimanis, B. L., Krumholz, H., Minchom, A., O'Connor, D., ... Peipert, J. D. (2024). Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials - insights from an expert virtual roundtable. EClinicalMedicine, 76, 102838. https://doi.org/10.1016/j.eclinm.2024.102838
Early phase clinical trials provide an initial evaluation of therapies' risks and benefits to patients, including safety and tolerability, which typically relies on reporting outcomes by investigator and laboratory assessments. Use of patient-reported outcomes (PROs) to inform risks (tolerability) and benefits (improvement in disease symptoms) is more common in later than early phase trials. We convened a two-day expert roundtable covering: (1) the necessity and feasibility of a universal PRO core conceptual model for early phase trials; (2) the practical integration of PROs in early phase trials to inform tolerability assessment, guide dose decisions, or as real-time safety alerts to enhance investigator-reported adverse events. Participants (n = 22) included: patient advocates, regulators, clinicians, statisticians, pharmaceutical representatives, and PRO methodologists working across diverse clinical areas. In this manuscript, we report major recommendations resulting from the roundtable discussions corresponding to each theme. Additionally, we highlight priority areas necessitating further investigation.
